Andre Tilton, MD
Family Medicine · New Orleans, LANPI 1306165097
Payments from drug & device makers
Across 505 payments — averaging $15.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Lilly USA, LLC$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$728
- Pfizer$688
- GSK$386
- Novo Nordisk$371
- plus $2K from 32 others
What the payments were for
- Food & beverage$8,054100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 152 | $2,339 |
| Lilly USA, LLC | 64 | $1,164 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 54 | $728 |
| Pfizer | 61 | $688 |
| GSK | 21 | $386 |
| Novo Nordisk | 20 | $371 |
| Amgen | 13 | $286 |
| AstraZeneca | 18 | $285 |
| Otsuka America Pharmaceutical, Inc. | 9 | $167 |
| Novartis | 10 | $164 |
| Orexo US, Inc. | 10 | $163 |
| Ardelyx, Inc. | 5 | $124 |
| Boehringer Ingelheim | 7 | $124 |
| Genentech USA, Inc. | 8 | $118 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $114 |
| Bayer | 5 | $94 |
| Gilead | 4 | $77 |
| Indivior Inc. | 3 | $75 |
| Teva Pharmaceuticals USA, Inc. | 4 | $73 |
| Biohaven Pharmaceuticals, Inc. | 4 | $70 |
| Vanda Pharmaceuticals Inc. | 2 | $62 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $52 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $47 |
| Astellas Pharma US Inc | 2 | $32 |
| Ironshore Pharmaceuticals Inc. | 2 | $30 |
| Kowa Pharmaceuticals America, Inc. | 2 | $26 |
| MDD US Operations, LLC | 2 | $25 |
| Abbott | 1 | $25 |
| Neurelis, Inc. | 1 | $21 |
| Phathom Pharmaceuticals, Inc. | 1 | $18 |
| Arbor Pharmaceuticals, Inc. | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $15 |
| Exact Sciences | 1 | $14 |
| Optinose US, Inc. | 1 | $13 |
| Merck | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Qiagen, LLC | 1 | $13 |
| Shire North American Group Inc | 1 | $13 |
How this compares
$8,063 in reported general payments places this provider in the 90th percentile of 1,469 family medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 127 | $142,553 |
| MounjaroTirzepatide | 64 | $68,604 |
| TrulicityDulaglutide | 56 | $65,818 |
| LinzessLinaclotide | 38 | $28,588 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 33 | $27,886 |
| XareltoRivaroxaban | 22 | $23,084 |
| JanuviaSitagliptin Phosphate | 24 | $21,911 |
| CreonLipase/Protease/Amylase | 12 | $20,211 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 92 | $19,365 |
| JardianceEmpagliflozin | 22 | $17,878 |
| TradjentaLinagliptin | 19 | $17,247 |
| EliquisApixaban | 20 | $17,210 |
| Nurtec OdtRimegepant Sulfate | 11 | $15,190 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 15 | $11,150 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $10,080 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $371 | $142,553127 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,164 | $134,422120 claims |
| AbbVieLinzess, Creon | $2,339 | $48,79950 claims |
| Boehringer IngelheimJardiance, Tradjenta | $124 | $35,12641 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $386 | $34,90249 claims |
| PfizerEliquis, Nurtec Odt | $688 | $32,39931 claims |
| MerckJanuvia | $13 | $21,91124 claims |
| Indivior Inc.Suboxone | $75 | $11,15015 claims |
| AstraZenecaSymbicort | $285 | $5,84021 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,469 family medicine providers in Louisiana.
Other family medicine in New Orleans
- Stephen JonesNew Orleans$513K
- Kristen ThomasNew Orleans$361K
- Ibrahim ZeinatyNew Orleans$13K
- Clinton GuilloryMonroe$18.5M
- Jason MorrisLake Charles$18M
- Michael SeepLake Charles$9.1M
- William NaboursLake Charles$3M
- Ramon VargasKenner$2.1M
- Joshua WhatleyLake Charles$366K
- Richard JeansonneMandeville$362K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.